Jodi T Williams

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Ankylosing Spondylitis

Top Venues

Journal of medicinal chemistry

Science advances

RSC medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A Ertel, Oliver Nayler, Christine Brotschi, Jodi T Williams, John Gatfield
A uniquely efficacious type of CFTR corrector with complementary mode of action. Science advances 10 (9) (2024)
Cyrille Lescop, Christine Brotschi, Jodi T Williams, Christoph P Sager, Magdalena Birker, Keith Morrison, Sylvie Froidevaux, Stéphane Delahaye, Oliver Nayler, Martin H Bolli
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. Journal of medicinal chemistry 67 (4) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Cyrille Lescop, Christine Brotschi, Jodi T Williams, Christoph P Sager, Magdalena Birker, Keith Morrison, Sylvie Froidevaux, Stéphane Delahaye, Oliver Nayler, Martin H Bolli
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. Journal of medicinal chemistry 67 (4) (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry 67 (4) (2024)
Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard, Christine Kuntz, Camille Forny, Judith Kamper, Rolf Studer, Alexandre Bossu, Eric A Ertel, Oliver Nayler, Christine Brotschi, Jodi T Williams, John Gatfield
A uniquely efficacious type of CFTR corrector with complementary mode of action. Science advances 10 (9) (2024)
Cyrille Lescop, Christine Brotschi, Jodi T Williams, Christoph P Sager, Magdalena Birker, Keith Morrison, Sylvie Froidevaux, Stéphane Delahaye, Oliver Nayler, Martin H Bolli
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. Journal of medicinal chemistry (2024)
Jodi T Williams, Martin H Bolli, Christine Brotschi, Thierry Sifferlen, Michel Alexander Steiner, Alexander Treiber, John Gatfield, Christoph Boss
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials. Journal of medicinal chemistry (2024)
Christine Brotschi, Martin H Bolli, John Gatfield, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T Williams, Christoph Boss
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats. RSC medicinal chemistry 15 (1) (2023)
Christine Brotschi, Martin H Bolli, John Gatfield, Catherine Roch, Thierry Sifferlen, Alexander Treiber, Jodi T Williams, Christoph Boss
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats. RSC medicinal chemistry 15 (1) (2023)